I may be mistaken, but I don't think the other indications are meant in terms of the application targeting indications beyond Generalized Anxiety Disorder. I think Mark mentioned them because as part of the IND, the company is collating data for psilocybin across other clinical trials for other indications as part of presenting a full profile of the main active ingredient of their drug candidate. I'd be pleased to be wrong, naturally.
I would really like to know what the trial design and stages are going to look like with Psi-GAD. Are we going straight for pivotal trials next year with a phase 2/phase 3 blended design like IHL-42x? If anyone knows this, please share!
- Forums
- ASX - By Stock
- IHL
- Ann: Incannex to Prepare IND Application for Psi-GAD
Ann: Incannex to Prepare IND Application for Psi-GAD, page-13
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online